Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

LaSara Medical Group vs Mevo Health

LaSara Medical Group
Graded #455

Lower grade

vs+5.700000000000003
Mevo Health
Graded #326

Higher grade

The verdict

Mevo Health takes it — 60.2/100 to 54.5/100.

Mevo Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Mevo Health (Mevo Health LLC, Delaware) is a direct-pay telehealth platform offering compounded semaglutide and tirzepatide in both injection and oral-tablet forms — a rare both-routes, both-molecules menu.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMevo Health +23
33
56
Dose & formulationMevo Health +19
64
83
Clinical oversightLaSara Medical Group +2
69
67
Labs & monitoringLaSara Medical Group +1
53
52
FulfillmentLaSara Medical Group +9
66
57
Contract termsLaSara Medical Group +27
47
20
LaSara Medical Group · left barMevo Health · right bar

The numbers

MetricLaSara Medical GroupMevo Health
WeighScore54.5/10060.2/100
GradeCC
Scorecard rank#455#326
Semaglutide$289/mo (compounded)$199/mo (all doses, compounded)
Tirzepatide$399/mo (bundle, compounded)$259/mo (all doses, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes
LaSara Medical Group

Graded #455 · C

Strengths

  • Multi-modality clinic — compounded GLP-1s alongside TRT, peptides, B12, NAD+, sermorelin, and enclomiphene
  • National telehealth plus an in-person option in Southern California — uncommon hybrid model
  • Free initial consultation
  • Active promotional pricing (30% off sitewide at the time of review)
  • GLP-1 pricing now published on product pages: compounded semaglutide from $233/mo, tirzepatide from $325/mo on annual bundles

Where it loses points

  • Legal entity name and state of incorporation not disclosed
  • Compounding pharmacy partner not named
  • LegitScript certification status not confirmed
  • Per-state availability not listed despite the national-telehealth claim
  • Lab work and ongoing monitoring inclusion not clearly disclosed for the multi-modality menu
Mevo Health

Graded #326 · C

Strengths

  • LegitScript verification badge on multiple pages
  • Publishes the FDA compounded-medication disclaimer
  • Four named board-certified physicians disclosed (Wasef, Suppa, Sakla, Chikando)
  • Both semaglutide and tirzepatide in injection and oral-tablet forms — rare in DTC
  • Public entry-level pricing surfaced

Where it loses points

  • States served not listed on any public page
  • Pharmacy partners not named (only '503A U.S. compounding pharmacies' with unlabeled logos)
  • No formal Medical Director role disclosed
  • Only 'as low as' entry pricing shown — no per-dose itemization
  • No SOC 2 certification claimed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard